Precision NeuroMed
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Precision NeuroMed (PNM) is a clinical-stage biotechnology company transforming the treatment of serious neurological diseases through precision brain delivery of biologic therapies, beginning with glioblastoma. Our lead asset, PNM-201, is a clinically validated, late-stage oncolytic protein targeting the driver of tumor recurrence and poor survival. In a prior Phase III trial, transformative long-term survival of 5–20+ years was observed when drug delivery was optimized. The overall outcome was limited not by lack of biological activity, but by trial execution and delivery variability - now resolved with modern, reproducible delivery systems. Through a capital-efficient path, we are positioned to establish a new standard of care in glioblastoma while unlocking a scalable precision delivery platform for multiple CNS diseases.
Company HQ City:
Redwood City
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
PNM-201 (IL13PE38QQR): a recombinant cytotoxin targeting the IL13a2 receptor with an enzymatic payload the irreversibly stops protein synthesis.
CEO
Sandeep Kunwar, MD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
Q1 '29
What is your next catalyst (value inflection) update?
Completion of Phase 2a study
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}